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 Abstract: 
The C-type lectin domain (CTLD) group 14 family of transmembrane glycoproteins 
consist of thrombomodulin, CD93, CLEC14A and CD248 (endosialin or tumour 
endothelial marker-1). These cell surface proteins exhibit similar ectodomain 
architecture and yet mediate a diverse range of cellular functions, including but not 
restricted to angiogenesis, inflammation and cell adhesion. Thrombomodulin, CD93 
and CLEC14A are expressed by endothelial cells, whereas CD248 is expressed by 
vasculature associated pericytes, activated fibroblasts and tumour cells amongst 
other cell types. In this article we review the current literature of these family 
members including their expression profiles, interacting partners, as well as 
established and speculated functions. We focus primarily on their roles in the 
vasculature and inflammation as well as their contributions to tumour immunology. 
The CTLD group 14 family share several characteristic features including their ability 
to be proteolytically cleaved and engagement of some shared ligands. Each family 
member has strong links to tumour development and in particular CD93, CLEC14A 









C-type lectin domain group 14 family 
There are 17 families in the C-type lectin domain (CTLD) containing superfamily described in 
humans. This superfamily comprises a range of remarkably diverse proteins that can be 
secreted or expressed on the cell surface. They mediate a wide range of functions including 
but not limited to inflammation, cell adhesion and carbohydrate recognition [1]. 
Thrombomodulin, CD248, CD93 and CLEC14A represent members of the CTLD group 14 
family which share common domain architecture (Figure 1). Each member is comprised of 
an N-terminal signal peptide and a CTLD containing 8 conserved cysteine residues. This is 
followed by a sushi-like or complement control protein (CCP) domain, and is also commonly 
referred to as a short consensus repeat. Next are a number of EGF-like domain repeats, 
THBD contains six, CD93 five, CD248 three and CLEC14A one. These are followed by a 
mucin-like region of variable length which is proline, serine and threonine rich and 
encompasses many predicted O-linked glycosylation sites. Finally, there is a single pass 
transmembrane region that connects to a cytoplasmic tail. 
The CTLD was originally described as a calcium (Ca2+) dependent carbohydrate binding 
domain, although not all CTLDs require Ca2+ or demonstrate carbohydrate binding activity. 
The overall CTLD fold is characterised by a so called “loop in a loop” structure stabilised by 
a conserved set of residues which contribute to a distinctive hydrophobic core [1]. CTLD 
containing proteins have been widely described in many species and can even be found in 
the Bordetella bronchiseptica bacteriophage [2]. Sushi domains exhibit extensive sequence 
variation but are generally characterised by 4 conserved cysteines (forming two disulphide 
linkages in a 1-4 and 2-3 pattern) and an invariant tryptophan, which contribute to preserving 
its tertiary structure [3]. The sushi domain is an extracellular motif that can contribute to 
protein-protein interactions, best exemplified in interleukin-15 receptor-α (IL-15Rα) 
recognition of IL-15 [4]. EGF-like domains are evolutionary conserved modules, which derive 
their name from the epidermal growth factor where they were originally described. EGF-like 
domains are found in a wide range of proteins, chiefly of animal origin and are frequently 
observed in tandem repeats. Each EGF module typically consists of 30-40 amino acids and 
includes six conserved cysteines which form three intramolecular disulphide bonds [5]. The 
highly glycosylated mucin region is commonly associated with adhesion proteins as 
described for CD164 [6] and offers protection against protein degradation by preventing 
access to proteases. In addition, the presence of many O-linked sugar moieties most likely 
allows proteins to adopt a more rigid and extended conformation [7]. All of the CTLD group 
14 family members have been detected at a much higher molecular weight than one would 
expect based on their primary amino acid sequences. These apparent disparities can be 
attributed to high degrees of post translational modifications, most likely glycosylation. 
Consistent with this hypothesis, when CD248 is treated with O-glycanase and sialase its 
molecular weight is reduced from 165 to 95 kDa when purified from human neuroblastoma 
cells [8]. It is interesting to note that electron microscopy analysis of thrombomodulin 
revealed an elongated molecule with a large globular nodule at one end and a smaller 
nodule at the other [9]. If we assume that the larger nodule is likely the CTLD, the smaller 
one is most likely comprised of the EGF repeats. Since the overall domain architecture of 
CTLD group 14 family members is relatively conserved, it is tempting to speculate that they 
all display a similar elongated structure with the membrane-distal CTLD interacting with its 
cognate ligands. Additionally, the domain layout of CTLD, sushi and EGF modules are 
reminiscent of the CTLD group 4 selectin family of cell adhesion molecules, albeit in a 
different order [10]. Similar to the group 4 family, there are numerous examples of the CTLD 
group 14 family mediating roles in adhesion (see below). 
Based on whole protein sequence alignment the family member with closest homology to 
CLEC14A is CD248 and CD93 is most closely related to thrombomodulin (Figure 2). It has 
been suggested that CD93 could have arisen from thrombomodulin by gene duplication 
events as each is present on chromosome 20 in humans [11]. 
Thrombomodulin 
Thrombomodulin (THBD or CD141) is the most extensively studied member of the CTLD 
group 14 family and is expressed by endothelium of all blood vessels and lymphatics [11,12]. 
It is also localised on a range of other cell types including but not restricted to monocytes, 
neutrophils and dendritic cells [13]. Thrombomodulin is expressed early in development and 
mice lacking the gene show embryonic lethality [14]. Interestingly, thrombomodulin deficient 
mouse embryos die at embryonic day 8.5 due to defects in non-endothelial tissue within the 
placenta, but reintroduction of thrombomodulin into the placenta allows normal development 
of embryos until day 12.5 [15]. This suggests two distinct roles for thrombomodulin during 
development, one in the placenta and  the other in the embryo. Nevertheless, 
thrombomodulin is the only family member that following genetic deletion causes embryonic 
lethality, suggesting that it exhibits an indispensable role. This lethal phenotype is not 
dependent on the CTLD or the cytoplasmic tail, as mice that lack these modules remain 
viable [16] [17]. Based on these considerations such embryonic lethality is most likely due 
disruptions in the thrombomodulin-mediated coagulation cascade elicited by the EGF 
domain tandem repeats (see below). 
Thrombomodulin and coagulation 
One of the major roles for thrombomodulin is regulating the coagulation cascade by binding 
to the serine protease thrombin [13]. The mode of recognition for this physiologically relevant 
co-factor involves the EGF modules of thrombomodulin as determined by the crystal 
structure of the thrombomodulin-thrombin complex [18]. This binding event inhibits pro-
coagulant thrombin-mediated hydrolysis of fibrinogen to fibrin, thereby inducing an anti-
coagulative effect [19]. Thrombomodulin-thrombin binding also increases by approximately 
1000 fold the thrombin-mediated cleavage and activation of the anti-coagulant serine 
protease protein C [20]. Activated protein C is involved in the inactivation of pro-coagulant 
factors FVa and FVIIIa [20,21]. In addition, thrombomodulin-thrombin complexes enhanced 
by approximately 1250 fold the activation of the anti-coagulant TAFI (thrombin activatable 
fibrinolysis inhibitor)  [22]. Therefore, in redirecting the cleavage activity of thrombin towards 
the activation of anti-coagulant proteins, thrombomodulin can dampen the coagulation 
cascade by different mechanisms. Recently, the regulators of angiogenesis angiopoietin-1 
(Ang-1) and angiopoietin-2 (Ang-2) have both been described as ligands for thrombomodulin 
[23]. Ang-2 binds with higher affinity than Ang-1 but both, by competing with thrombin, can 
disrupt thrombomodulin-thrombin interactions leading to suppression of thrombin mediated 
anti-coagulant functions. The wide ranging roles of thrombomodulin in coagulation are well 
documented elsewhere [23,24] and hence will not be discussed in any depth. We also direct 
the reader towards a recent review exploring the “non-traditional roles” of thrombomodulin 
[25]. 
Thrombomodulin and angiogenesis 
Pro-angiogenic effects have been reported for a recombinant form of soluble 
thrombomodulin encompassing six contiguous EGF modules and the mucin-like region 
(thrombomodulinEGF-Mucin), resulting in increased endothelial proliferation, tube formation, 
migration and upregulation of matrix metalloprotease expression [26]. This recombinant 
protein also elicited pro-angiogenic effects on endothelial progenitor cells (EPCs) through a 
phosphoinositide 3-kinase (PI3K) dependent pathway [27]. Furthermore thrombomodulinEGF-
Mucin demonstrated endothelial protective roles chiefly by guarding against apoptosis again 
via the PI3K pathway [28]. These roles are thought to be dependent on the EGF domains 
which can bind to and activate fibroblast growth factor receptor 1 (FGFR1) [29]. The fifth 
EGF domain of thrombomodulin alone (thrombomodulinEGF5) has also demonstrated pro-
angiogenic function as well as cytoprotective effects on endothelium [30]. This cytoprotective 
phenomenon was suggested to be independent of thrombomodulin-thrombin interactions 
and instead due to upregulation of anti-apoptotic protein myeloid-cell leukaemia-1 (MCL1) 
[31]. A subsequent study revealed that this cytoprotective outcome was triggered by 
thrombomodulinEGF5 binding to G-protein coupled receptor-15 (GPR15) on endothelial cells, 
leading to activation of endothelial nitric oxide synthase (eNOS) and extracellular-signal 
regulated kinase (ERK) signalling, an effect that was abolished in GPR15 deficient mice [32]. 
Recently, the minimal fragment of thrombomodulinEGF5 necessary for binding to GPR15 and 
promoting pro-angiogenic function was identified as a 19 amino acid peptide, that includes 
an intramolecular disulphide bond which adopts a loop structure similar to that observed for 
the prototypical EGF [29,33]. However, whether thrombomodulin can bind to GPR15 whilst 
attached to the cell membrane, or if proteolytic processing is essential, is yet to be 
determined. 
These pro-angiogenic signals mediated by the thrombomodulin EGF5 domain can be 
abolished when the soluble extracellular domain (ECD) contains the CTLD [34]. The CTLD 
of thrombomodulin binds to Lewis Y antigen, which is a cell surface tetrasaccharide that is 
predominantly expressed during development and tumourigenesis [35]. Relatedly, soluble 
CTLD alone can mediate aberrant effects in angiogenesis assays, presumably by virtue of 
its interactions with Lewis Y antigen localised on epidermal growth factor receptor-1 
(EGFR1), thereby inhibiting its activation [34]. These findings suggest that the  
thrombomodulin CTLD exhibits roles distinct from the EGF domains and may be functionally 
dominant in its soluble form, due to its ability to negate EGF domain dependent effects. The 
CTLD of membrane-bound thrombomodulin has been shown to bind to the extracellular 
matrix protein fibronectin, an interaction which activates focal adhesion kinase (FAK) 
phosphorylation and upregulates matrix metalloproteinase-9 (MMP9) [35,36]. The 
thrombomodulin-fibronectin interaction occurs on tumour blood vessels in murine melanoma 
suggesting that this interplay may serve as a putative target for anti-angiogenic therapy, 
although an in-depth understanding of this interaction in healthy tissues would first need to 
be considered. Thrombomodulin cell surface expression can be regulated by binding of the 
CTLD to Kringle 1-5, a proteolytically cleaved fragment of plasminogen [37]. This binding 
event results in thrombomodulin internalisation and degradation, negating the pro-
angiogenic roles of membrane bound thrombomodulin. 
 
Thrombomodulin and cancer 
Thrombomodulin expression has been described in multiple cancer types on the 
endothelium and tumour cells [38,39]. In genetically engineered mice expressing a mutant 
form of thrombomodulin with severely compromised thrombin binding primary tumour growth 
was unaffected whereas lung metastasis was significantly enhanced [40]. The authors 
suggested this observation was due to prolonged survival of tumour cells in the lung and 
demonstrated that this effect was attributed to the thrombin binding function and not the N-
terminal CTLD. A whole host of studies in different tumour settings (lung, colorectal, cervical, 
prostate and bladder) postulate a role for thrombomodulin overexpression in reversing 
epithelial mesenchymal transition (EMT) [41–46]. Indeed, a more comprehensive review of 
the role of thrombomodulin in tumour biology has been documented [38]. The overall 
findings seem to indicate that thrombomodulin expression correlates with a good prognosis 
and expression is abolished in more aggressive and highly metastatic tumour types. 
 
Thrombomodulin and the immune system 
Thrombomodulin has been described to have roles in inflammation some of which are linked 
to its anticoagulant function. This is best exemplified by protein C triggering an anti-
inflammatory signalling cascade by inhibiting tumour necrosis factor-α (TNFα) production in 
response to lipopolysaccharide (LPS) [47]. Independent of its roles in coagulation inhibition, 
thrombomodulin CTLD can bind to the pro-inflammatory molecule high-mobility group protein 
B1 (HMGB1), leading to suppression of inflammation and protection against LPS-induced 
lethality [48]. A more recent study highlighted that the thrombomodulin-HMGB1 interaction 
allows the EGF domain bound thrombin to proteolytically cleave HMGB1 [49]. The 
inactivation of HMGB1 has potential implications on immunogenic cell death events following 
anti-cancer intervention invoked by chemotherapeutic agents or radiotherapy, whereby 
HMGB1 released by dying cells serve as damage associated molecular patterns activating 
antigen presenting cells and facilitating presentation of tumour antigens [50]. The 
thrombomodulin CTLD has also been shown to reduce the adhesion of polymorphonuclear 
leukocytes to endothelium [51]. The authors proposed that this a process was dependent on 
thrombomodulin binding to Lewis Y antigen and therefore blocking its availability to bind 
leukocytes and aid subsequent transmigration. Conversely, leukocytes have been suggested 
to directly recognise the mucin-like region of thrombomodulin through leukocyte adhesion 
integrins lymphocyte function associated antigen-1 (LFA-1) and Mac-1 [52]. 
Thrombomodulin EGF domains were found to markedly suppress LPS induced inflammatory 
signalling pathways in macrophages by associating with the pattern recognition receptor 
CD14, and that this inhibitory effect was also dependent on the serene, threonine rich 
domain [53].  
ThrombomodulinEGF5 also has the capacity to engage T-cells bearing GPR15 [54]. This 
results in immunosuppression of T-cell responses and facilitates differentiation of regulatory 
T-cells (Tregs). In addition, recombinant thrombomodulin
EGF5 was shown to inhibit dendritic 
cell activation. Taken together, this provides a possible rationale for recombinant 
thrombomodulin mediated alleviation of graft versus host disease (GVHD) in mouse models 
of haematopoietic stem cell transplantation. More importantly, it reconciles with clinical 
observations that increased expression of thrombomodulin can reduce GVHD in patients 
[30,55]. This immunosuppressive role of thrombomodulin could also have relevance in 
tumour immunology as thrombomodulin expressed in the tumour microenvironment has the 
potential to expand anti-inflammatory and pro-tumour Tregs, a cell type that contributes to 
tumour immune evasion mechanisms [56]. However, these findings are contrary to 
observations reporting thrombomodulin as a good prognostic factor, and its role in 
immunosuppression may be outweighed by its function in EMT and aggressiveness. 
 
Thrombomodulin shedding 
There are many transmembrane proteins that are specifically shed from the cell membrane 
to activate or deactivate distinct protein functions in angiogenesis and other physiological 
processes. Examples include the membrane bound epidermal growth factor precursor 
proteins, which are cleaved by metalloproteinases such as ADAM10 (a disintegrin and 
metalloproteinase-10) and ADAM17 resulting in growth factor activation [57]. Conversely, the 
EGF receptor itself can be subjected to proteolytic cleavage thereby suppressing 
downstream signalling functions [58].  
Thrombomodulin can be cleaved by the serine protease rhomboid-like 2 (RHBDL2) at a site 
proximal to the transmembrane domain, resulting in release of the entire extracellular 
domain (ECD) [59]. This RHBDL2 cleaved form of thrombomodulin can increase migration 
and wound healing in keratinocytes [60]. Also, the full-length thrombomodulin-ECD has also 
been shown to be cleaved from the endothelial cell surface after incubation with the 
neutrophil proteases elastase, cathepsin G and proteinase 3 [61]. Soluble thrombomodulin 
has been detected in human blood, urine and synovial fluid [62–64]. Indeed, monitoring 
serum levels of soluble thrombomodulin may be important as it can positively correlate with 
disease status such as systemic lupus erythematosus [65]. 
The thrombomodulin CTLD can also be cleaved leaving the remainder of the molecule intact 
upon the cell surface, an event that is most likely facilitated by matrix metalloproteinases 
(MMPs) [66]. Although, these cleavage events are yet to be explicitly shown in vivo, it is 
noteworthy that two forms of thrombomodulin have been isolated from human urine [63]. 
Characterisation of these fragments by N-terminal sequencing revealed that one form 
encompasses the EGF repeats and the mucin-rich region and retained the ability to bind 
thrombin. In contrast, the second fragment corresponded to the equivalent molecular weight 
for the N-terminal CTLD and failed to bind thrombin. Furthermore, four different versions of 
thrombomodulin were detected in human plasma suggesting even more potential cleavage 
sites [67]. Indeed, the physiological relevance of these different fragments requires further 
investigation. 
In summary, these findings of differential shedding along with the distinct biological function 
of each thrombomodulin sub-domain offers a scenario where one molecule can be 
proteolytically processed in different ways to elicit opposing effects. The shedding of 
thrombomodulin is likely a tightly regulated process in which specific domains are released 
depending on the requirement for pro or anti-angiogenic signals, as well as pro or anti-
inflammatory outcomes. 
 
Additional roles for thrombomodulin 
Along with its vital roles in regulating blood coagulation and inflammation, thrombomodulin 
also reportedly contributes to cell-cell adhesion, an event which is dependent upon the 
CTLD [68]. This pro-adhesion role was Ca2+ dependent and could be abolished with CTLD 
specific antibodies or addition of mannose, chondroitin sulphate A or C. This suggests that 
the thrombomodulin CTLD serves as a conventional Ca2+ dependent carbohydrate binding 
lectin. 
The cytoplasmic tail of thrombomodulin has been proposed as a ligand for the intracellular 
adaptor protein ezrin [69], a member of the ezrin-radixin-moesin (ERM) family of proteins 
that link transmembrane proteins to the actin cytoskeleton [70]. This reinforces the likelihood 
of thrombomodulin mediating cell adhesion events. Consistent with this, knockdown of 
thrombomodulin can compromise the integrity of E-cadherin mediated cell-cell contacts, 
potentially implicating thrombomodulin downregulation in the induction of epithelial 
mesenchymal transition in cancer [41]. A summary of thrombomodulin protein interactions is 
displayed in Figure 3. 
CD248 
CD248 also known as endosialin or tumour endothelial marker-1 (TEM-1) is the prototypical 
member of the CTLD group 14 family. It was first discovered as an antigen detected by the 
antibody FB5, which stained human tumour sections with patterns resembling blood vessels, 
but not healthy tissues [8]. This led the authors to describe CD248 as a marker for tumour 
endothelium, although it could not be detected in cultured human umbilical vein endothelial 
cells (HUVEC). The study did however demonstrate that it was a highly glycosylated cell 
surface glycoprotein leading to its proposed name at the time; endosialin. CD248 was later 
identified as a marker of tumour endothelium in studies involving serial analysis of gene 
expression (SAGE) of vessels purified from human colorectal cancers in comparison to 
healthy colon vessels, hence its alternative name TEM-1 [71]. Despite this, it is now widely 
accepted that CD248 is expressed by perivascular cells, stromal fibroblasts, mesenchymal 
stem cells and some tumour cells but not adult endothelium [72–74]. The expression of 
CD248 on perivascular cells but not on endothelium in vivo was unequivicocally 
demonstrated using multiple fluorescent labelling of human glioma sections [75]. The study 
by St. Croix and colleagues which originally identified CD248 as TEM-1 utilised CD146 or 
melanoma cell adhesion molecule (MCAM) antibodies to enrich the endothelium. Since 
MCAM also serves as a marker for pericytes, these samples likely contained perivascular 
cells as well as endothelium explaining the enrichment of CD248 [72,76]. The proposed 
expression of CD248 on EPCs may have also added to this confusion [77]. 
CD248 expression 
CD248 is expressed during development and is first detected in mice at embryonic day 9.5 
[78]. CD248 expression is mostly diminished in postnatal organs except for the kidney 
glomeruli and the uterus. Mice deficient in CD248 are viable and display no obvious defects, 
suggesting compensatory mechanisms may be employed during development [79]. 
However, a marked decrease in tumour growth, metastasis and invasion was observed 
when CD248 deficient mice were challenged with human colorectal cancer xenografts. This 
defect in tumour growth and metastasis was only evident with abdominally implanted tumour 
cells, whereas subcutaneous implants displayed no difference relative to control animals. 
Further studies revealed that expression of CD248 exhibited negligible effects on primary 
tumour growth but increased metastasis formation in mouse models of breast cancer [80]. 
Such pro-metastatic effects were attributed to CD248 expressing pericytes enhancing 
tumour cell intravasation. Elevated CD248 expression also correlated with greater 
metastasis and poorer survival in human breast cancer patients.  
CD248 expression has been reported to be induced by hypoxia, predominantly involving the 
transcription factor hypoxia inducible factor-2α (HIF-2α) [81]. This could explain the high 
levels of CD248 observed in the tumour microenvironment which is often poorly perfused 
and contains areas of hypoxia [82]. Upregulation of CD248 can also arise in response to the 
growth factors FGF-2, EGF and platelet derived growth factor-BB (PDGF-BB), which is 
further enhanced under hypoxic conditions [83]. 
CD248 expression has been described on naïve human CD8+ T-cells, where it can 
negatively regulate proliferation [84]. CD248 is expressed on stromal cells in secondary 
lymphoid organs and is required for correct secondary lymph node expansion in models of 
vaccination [85]. However, CD248 was not essential for correct spatial organisation of T and 
B-cells in this model. 
CD248 is expressed in the fibroblasts and pericytes of synovial tissue from patients with 
rheumatoid arthritis and psoriatic arthritis [86]. CD248 has also been identified in the sub-
lining layer of a distinct subset of synovial fibroblasts [87]. CD248 knockout mice and mice 
lacking the cytoplasmic domain of CD248 both showed reductions in experimental arthritis 
compared to wild type animals, and displayed a marked reduction in synovial inflammation 
[86]. 
 
CD248 interaction partners and biology 
CD248 has been reported to interact with the ECM proteins fibronectin and collagens I and 
IV [88]. The interaction of CD248 with fibronectin increased cell adhesion and was 
dependent upon the N-terminus of fibronectin and the CTLD of CD248. Consistent with 
these data the CTLD specific monoclonal antibody MORAb-004 (ontuxizumab) could block 
CD248 binding to fibronectin and collagen I. Also, siRNA mediated knockdown of CD248 
resulted in reduced migration and proliferation of fibroblasts, reinforcing a putative role in 
adhesion [89]. Interestingly, a characteristic feature identified in Chinese hamster ovary 
(CHO) cells overexpressing CD248 is the upregulation of MMP9, thereby implicating CD248 
in ECM degradation, a key step in sprouting angiogenesis as well as tumour metastasis and 
invasion [88]. Further evidence in support of CD248 associating with the ECM stemmed from 
immunofluorescent staining with CD248 ECD fused to an Fc tag (CD248-ECD-Fc), this 
staining was only observed in the ECM from endothelial cells and could partially co-localise 
with fibronectin [75]. More recently, we have shown direct interaction of CD248 with the 
endothelial ECM protein multimerin-2 (MMRN2) [75,90]. This interaction was dependent 
upon the CTLD of CD248 and CD248-ECD-Fc staining could partially co-localise with 
MMRN2 on HUVEC, this may clarify previous findings involving the CD248-ECD binding to 
the endothelial ECM [90]. 
Another ligand identified for CD248 was the secreted galectin-3 (Mac-2) binding protein 
Mac-2BP and this interaction proved to be carbohydrate and Ca2+ independent [91]. The 
CD248 interaction was mapped to two C-terminal domains of Mac-2BP and these have been 
previously implicated in binding galectin-3, collagen V and VI and nidogen, suggesting 
overlapping binding sites [92]. This interaction invokes repulsion of fibroblasts and HeLa 
cells expressing CD248 and Mac-2BP respectively. Moreover, this phenomenon was 
reduced following siRNA induced gene-silencing of either molecule. Mac-2BP is upregulated 
in the tumour cells of many different types of cancer and has been associated with increased 
metastasis and decreased survival in lung cancer patients [93]. These findings strengthen 
the likelihood of CD248-Mac-2BP interactions occurring during tumorigenesis. It is currently 
unknown whether the therapeutic antibody ontuxizumab can block CD248 binding Mac-2BP 
or MMRN2, a question that will likely impact novel future clinical interventions that target 
CD248. 
There is evidence to suggest that the cytoplasmic tail of CD248 is involved in tumour 
development, as mice lacking this domain display reduced tumour growth in T241 
fibrosarcomas and Lewis lung carcinomas [94]. The cytoplasmic tail has also been predicted 
to contain a PDZ binding site and three potential phosphorylation sites, although to date 
identification of CD248 intracellular domain interactors have proved elusive [73,95]. A 
summary of CD248 protein interactions is summarised in Figure 4. 
CD248 implications in angiogenesis 
CD248 deficient mice displayed no gross defects in developmental angiogenesis or wound 
healing, but abnormalities were clearly apparent in tumour models of both the full gene 
deletion and the cytoplasmic deletion, resulting in smaller tumours exhibiting increased 
vessel density [79,94]. Curiously, defects in tumour growth were not observed in all tumour 
models and the underlying mechanism remains unclear. Increased vascularity is also found 
in CD248 deficient mouse models of glioblastoma multiforme, but there are no differences in 
tumour growth compared to wild type animals [96]. These observations of increased vessel 
density may be rationalised by findings connecting CD248 with regulation of vascular 
patterning [75]. This function of CD248 was uncovered when HUVEC treated with plate 
bound CD248 (to mimic pericyte expression), exhibited higher levels of apoptosis. This study 
highlighted the prospect of CD248 mediating a key role in vessel regression and pruning and 
emphasised for the first time that pericytes could be linked to such functions. Moreover these 
observations underline the possible therapeutic potential of the CD248-ECD for inducing 
vessel regression and vascular normalisation, which might conceivably increase the delivery 
of chemotherapeutic agents into tumour tissue [97]. Likewise, this vessel normalisation effect 
has been shown to allow more efficient infiltration of effector immune cells into tumours [98]. 
CD248 has also been implicated in the platelet derived growth factor (PDGF) signalling 
cascade [99]. For example, following CD248 knock down in pericytes, PDGF mediated 
proliferation is reduced. Furthermore, CD248 knockout mice displayed defects in sprouting 
angiogenesis but not splitting (intussusceptive) angiogenesis in skeletal muscle [100]. Such 
defects could be recapitulated in mice treated with PDGFRβ inhibitors reinforcing a role for 
CD248 in PDGF signalling.  
 
CD248 in cancer  
Elevated CD248 expression levels on tumour associated stroma have been reported in 
various primary tumour types including glioma, colorectal, melanoma as well as brain 
metastases [75,101–103]. CD248 expression has also been associated with worse outcome 
in patients with breast or colorectal cancer and could serve as a prognostic marker 
[104,105]. CD248 is expressed in numerous tumour cell lines and clinical samples of 
sarcomas and neuroblastomas, but is absent in cancer cells of epithelial origin [74]. Indeed, 
highly malignant “side population” sarcoma cells with some characteristics of cancer stem 
cells express CD248 [106]. These highly invasive side populations are also CD248 positive 
in osteosarcoma [107]. For these reasons there has been a substantial drive into developing 
innovative strategies of targeting CD248 for tumour therapy.  
Targeting CD248 has been attempted mainly by antibody based therapeutic approaches. 
One of the first preclinical attempts utilised single chain variable fragment (scFv) antibody-
like molecules generated against CD248 to successfully direct cytotoxic agents to 
neuroblastoma cells in vitro [108]. Internalising antibodies against CD248 coupled with anti-
human IgG toxin conjugated antibodies revealed cell cytotoxic effects on CD248 expressing 
cancer cell lines in vitro [74]. Such antibodies were developed as full antibody drug 
conjugate (ADC) molecules utilising conjugation to tubulin inhibiting drugs [109]. 
Administration of these ADCs retarded tumour growth in multiple xenograft models. Another 
ADC against CD248 has been developed conjugated to a DNA-binding duocarmycin 
derivative which has shown therapeutic efficacy in a human osteosarcoma xenograft model 
[110]. The previously described CTLD specific CD248 antibody ontuxizumab, has been 
utilised as a possible diagnostic imaging tool through use of 125Iodine conjugation and 
positron emission tomography (PET) [111]. This technique resulted in rapid tumour uptake 
and real-time visualisation of tumour burden and CD248 localisation in mice. Some more 
recent developments have involved the generation of human CD248 knock-in mice to study 
the in vivo effects of ontuxizumab [112]. Indeed, upon administration of ontuxizumab into 
B16 melanoma bearing mice, tumour growth was significantly reduced by up to 70%. This 
was presumably due to increases in microvessel density and the presence of non-
functioning tumour blood vessels; phenocopying previous findings in CD248 knock-out 
animals. This study also showed downregulation of surface expression of CD248 on 
pericytes by internalisation after ontuxizumab treatment in vitro and in vivo. The ontuxizumab 
humanised CD248 antibody has recently completed phase I clinical trials in patients with 
different types of solid tumours with preliminary anti-tumour responses being observed [113]. 
However a randomised phase II study of ontuxizumab in metatastatic colorectal cancer 
patients with chemotherapy resistance showed no additional clinical benefit compared to 
placebo [114]. Moreover, a phase I trial of ontuxizumab in multiple different relapsed solid 
tumours showed no objective response [115]. A Japanese phase I trial investigating 
ontuxizumab use in patients with solid tumours which failed to respond to standard therapy 
showed potential activity with tumour shrinkage being observed in a third of HCC patients 
[116].  The varied expression profiles of CD248 in human cancers will need to be carefully 
scrutinised whilst considering therapeutic CD248 targeting approaches. With this in mind 
there is a strong possibility that CD248 targeting strategies may only demonstrate clinical 
benefits in tumour types that specifically upregulate CD248. Alternatively, targeting of CD248 
tumour cell expression will likely select for tumour cell clones that do not express CD248 and 
could therefore lead to drug resistance. Hence it may be advantageous to instead target 
stromal and vessel associated cells in the tumour microenvironment, as they would be less 
prone to acquiring such resistance. 
DNA vaccine approaches against CD248 have also been attempted preclinically, with anti-
tumour effects being reported in both the prophylactic and therapeutic vaccine setting [117]. 
The DNA construct consisted of murine CD248 fused to a fragment of tetanus toxoid, which 
circumvents tolerance to the self-protein allowing triggering of an adaptive immune 
response. The authors described CD4+ and CD8+ T-cell clones that were specific for CD248 
epitopes as well as tumour specific antigens. The vaccination did not detrimentally affect 
wound healing or reproduction.  
The targeting of CD248 will likely be dependent on the tumour type as CD248 expression 
upregulated in hepatocellular carcinoma (HCC) patients in hepatic stellate cells, which are 
specialised pericytes found in the liver vasculature, was found to be protective correlating 
with better outcomes [118]. Furthermore, inducible models of HCC in CD248 knock-out mice 
displayed enhanced liver tumour progression relative to wild type controls. 
CD248 shedding 
There are numerous reports describing soluble variants of CD248, suggesting its ECD may 
be shed from the cell surface as highlighted for other CTLD group 14 family proteins. CD248 
has been suggested as a possible biomarker after it was purified from ascites fluid of 
patients with stage IV ovarian cancer [119], and pancreatic cancer [120]. CD248 can be 
immuno-precipitated from human serum in a fully glycosylated form of around 150-120 kDa, 
likely corresponding to the full ECD [121]. In this same study, a highly sensitive and specific 
assay was developed using two different CD248 monoclonal antibodies to evaluate CD248 
levels in patient blood. Surprisingly, there was no significant difference in serum levels of 
soluble CD248 from colorectal cancer patients compared with healthy controls, which may 
limit its utility as a predictive biomarker particularly in this tumour setting. 
The protease responsible for cleaving CD248 from the cell surface has yet to be identified, 
although further investigation of this proteolytic event together with elucidating the precise 
role of the soluble form will be of great importance within the CD248 therapeutic targeting 
field. It is possible that high serum levels of soluble CD248 could adversely affect the clinical 
efficacy of CD248 antibodies, by sequestering such therapeutics within the circulation. 
 
CD93 
CD93 was first described as a receptor for the complement component C1q, hence its 
alternative name C1q receptor-1 (C1qR1 or C1qRp) [122,123]. A subsequent study revealed 
that CD93 failed to engage C1q, but was instead implicated in cellular adhesion events 
(McGreal et al. 2002). CD93 is expressed by endothelial cells and neurons and various cells 
of the haematopoietic system, including monocytes, neutrophils, B cells, natural killer (NK) 
cells, naïve T cells, platelets and haematopoietic stem cells [124–129]. It is also highly 
expressed on the tumour associated vasculature. In a recent example, elevated levels of 
CD93 expression was detected on human colorectal carcinoma sections [130]. Interestingly, 
this study also examined soluble levels of CD93 within patient plasma and found a 30% 
reduction in colorectal carcinoma patients compared with healthy controls. CD93 has been 
described as a key gene in a proposed “tumour angiogenesis signature” determined by 
meta-analysis of 959 breast cancers, 170 renal cancers and 121 head and neck cancers 
[131]. Moreover, CD93 has been identified as a member of a group of genes that are vastly 
upregulated in high grade glioblastoma tumour vasculature [132]. This high expression 
profile was later confirmed at the protein level and correlated with poorer survival [133]. 
Upregulated vascular expression of CD93 has also been described in nasopharyngeal 
carcinoma, as well as tumours of the eye including retinoblastoma and choroidal melanoma 
[134], [135], and correlates with a worse survival outcome. More recently the CD93 CTLD 
has been derived from E.coli expression systems that allow disulphide bond formation  has 
been purified to homogeneity allowing preliminary structural analyses using nuclear 
magnetic resonance (NMR) approaches[136]. This study revealed the CD93 CTLD does not 
bind Ca2+  and ongoing experiments will undoubtedly resolve the three dimensional structure 
and provide further molecular and functional insights into this family member. 
CD93 expression 
During mouse development CD93 is expressed at embryonic day 9 and is detected in the 
vasculature including the inter-segmental vessels [137]. CD93 deficient mice were viable 
and displayed no obvious abnormalities, but exhibited reductions in clearance of apoptotic 
cells [138]. A defect in antibody secretion in plasma cells was also a characteristic feature of 
CD93 knockout mice [129]. Intriguingly, only CD93 deficient female mice display aberrations 
in tumour growth and perfusion in orthotopic glioblastoma and fibrosarcoma models [133]. 
CD93 has been identified as a gene that is downregulated upon VEGF blockade by use of 
bevacizumab in patented studies performed by Genentech, thereby reinforcing its roles in 
angiogenesis (Bais et al. 2011). Similarly, another report highlighted that CD93 protein 
expression was diminished upon pharmacological inhibition of VEGFR2 and FGF1 with 
brivanib alaninate [139]. 
CD93 and inflammation 
Mice deficient in CD93 when subjected to experimental peritonitis displayed increased 
leukocyte infiltration, and this effect was not restricted to a particular cell type [140]. CD93 
also conveys neuroprotective roles as it is upregulated in murine models of stroke [141]. This 
effect was also observed at the protein level in several cell types including endothelial cells, 
microglia and macrophages. Moreover, cerebral ischemia in CD93-/- mice resulted in 
enhanced neuro-inflammation compared to wild type animals. Based on the CD93 
expression profile within the tumour vasculature and its potential anti-inflammatory roles, it is 
plausible to contemplate that CD93 serves as an immunosuppressive molecule, limiting 
immune cell infiltration and facilitating tumour immune evasion mechanisms. 
CD93 interaction partners and biology 
Silencing of CD93 by RNA interference in HUVEC impaired proliferation, migration, adhesion 
and sprout formation [142]. Subsequent studies validated these effects with disruptions 
observed in adhesion, migration and tube formation [133,134]. A monoclonal antibody raised 
against human CD93 (clone 4E1) which binds between the CTLD and sushi domains 
demonstrated anti-angiogenic activity in Matrigel assays both in vitro and in vivo, reiterating 
its roles in endothelial biology [142]. Another study showed that the recombinant form of the 
CD93 ECD can engage the cell surface of THP-1 cells indicating the expression of a 
currently unknown CD93 ligand in this monocyte cell line [143]. 
Ligand binding studies of CD93 with a variety of ECM proteins revealed a lack of binding to 
all proteins tested including; collagen I and IV, gelatin, laminin, vitronectin and fibronectin 
[144]. The only known extracellular interacting partner for CD93 was recently identified as 
the endothelial specific ECM protein MMRN2 [90]. This interaction is dependent on the 
CTLD of CD93 and by combining structural modelling with site directed mutagenesis a 
predicted long-loop region of this structure was proposed to be critical for binding to 
MMRN2. This offers a platform for developing innovative therapeutics that specifically target 
CD93 to interrupt this interaction. The CD93-MMRN2 interaction was later independently 
validated and surface plasmon resonance was used to characterise the interaction and 
determine binding affinities [145]. A key residue within the coiled-coil domain of MMRN2 
(F238) was proposed as being integral for CD93 binding. Interestingly, this study also 
provided an explanation for the previously described anti-angiogenic effects of the CD93 
antibody 4E1, as it could interrupt the CD93-MMRN2 interaction. 
The CD93-MMRN2 interaction was also involved in the proper deposition and organisation 
of fibronectin a process termed fibrogenesis [146]. In CD93 deficient mice the fibronectin 
matrix was disrupted in retinal angiogenesis and vessels in orthotopic models of 
glioblastoma [146]. In the same study the use of specific antibodies that detect activated 
α5β1 integrins, revealed disruption of this activated integrin in CD93 knock-out mice. During 
retinal angiogenesis CD93 is expressed on filopodia while MMRN2 expression is absent 
from these protrusions but present in the surrounding ECM. Finally the authors showed that 
MMRN2 and fibronectin expression is upregulated in high grade human glioma [146]. Co-
localisation of CD93 and MMRN2 expression has been demonstrated in vessels of a range 
of different solid human tumours including melanoma, Ewing’s sarcoma, ovarian carcinoma 
and glioma amongst others [145,146]. 
The cytoplasmic domain of CD93 encompasses a positively charged juxtamembrane region 
that binds to the adaptor protein moesin [147]. Moesin is a member of the ERM family of 
proteins, which like ezrin, anchors proteins to the actin cytoskeleton [70]. In knock down 
studies involving CD93, adherens junctions were disrupted [133]. Strikingly, reintroduction of 
wild type CD93 but not CD93 lacking the moesin binding motif, restored adhesion junctions 
and highlighted the importance of CD93-moesin interactions in maintaining the integrity of 
endothelial cell adhesion. Relatedly, CD93 deficient mice display increased permeability in 
blood vessels possibly due to disruptions in tight junctions [140]. Another intracellular binding 
partner for CD93 has been defined as GIPC (Gα interacting protein (GAIP) interacting 
protein C-terminus) [148] an adapter protein that contributes to arterial maturation and mural 
cell coverage [149]. The binding of GIPC was not entirely dependent on the positively 
charged juxtamembrane region of CD93 but also the final C-terminal 11 amino acids of the 
cytoplasmic tail. CD93 was originally predicted to bind to the E3 ubiquitin ligase Cbl, as the 
CD93 cytoplasmic domain contains a binding motif that is also found in the Cbl binding 
protein APS (adapter with pleckstrin homology and Src homology-2 domains) [150]. CD93 
binding to Cbl was proved experimentally by coimmunoprecipitation of HUVEC, and this 
interaction was abolished upon knockdown of the ECM adhesion molecule β-dystroglycan 
[144]. This study proposed that the crosstalk between the laminin binding protein β-
dystroglycan and CD93 led to endothelial cell adhesion and migration. Upon knockdown of 
CD93, β-dystroglycan expression was increased in endothelium and vice versa. The authors 
suggested that upon laminin binding to β-dystroglycan src kinase phosphorylates specific 
tyrosine residues in the cytoplasmic tail of CD93, which in turn facilitates binding to Cbl. In 
this setting Cbl may serve as an adapter protein rather than its ubiquitin ligase role. Finally, a 
role in Ca2+ signalling has been proposed for CD93 as stimulation with monoclonal 
antibodies results in release of intracellular Ca2+ in rat natural killer cells [126]. However, 
although the molecular mechanism governing this signalling event is not well understood it is 
possible to speculate that the antibody either stimulates CD93 signalling or blocks CD93 
binding to other ligands. A summary of the protein interaction partners of CD93 are 
summarised in Figure 5. 
CD93 shedding 
Soluble CD93 has been detected in human plasma, described to be a protein released from 
HUVEC and also a component of their ECM [148,151,152]. Several studies have highlighted 
that levels of soluble CD93 directly correlate with disease status; in plasma it has been 
proposed as a potential biomarker for coronary artery disease and is elevated in synovial 
fluid of rheumatoid arthritis patients [143,153]. In another study, soluble CD93 was proposed 
as a marker for allergic inflammation as it is reportedly shed from the cell surface of 
monocytes and neutrophils, which is likely to be dependent on metalloproteinases, although 
the major sheddase ADAM17 is not involved [154]. This cleavage event most likely liberates 
the entire ECD of CD93 and can be stimulated by tumour necrosis factor-α (TNFα) or LPS. 
This inflammation induced shedding of CD93 was subsequently confirmed by in vivo 
experiments, and macrophages were suggested as the main source of soluble CD93 [155]. 
Conversely, elevated levels of soluble CD93 in peritonitis fluid were shown to be dependent 
on non-haematopoietic cells, likely from endothelium [140]. Finally, soluble CD93 has been 
suggested to induce differentiation of monocytes by as yet undefined mechanisms [143].  
Soluble recombinant CD93 encompassing solely the five tandem EGF repeats and mucin 
domain of CD93 mediate pro-angiogenic effects on endothelial cells, increasing proliferation 
and migration of HUVEC and promoting angiogenesis in vivo [156]. Although these pro-
angiogenic signals were also induced with the full-length CD93-ECD, constructs lacking the 
CTLD elicited more potent effects by enhancing the EGFR1 mediated PI3K signalling 
pathway; similar results were observed with recombinant soluble forms of thrombomodulin 
encompassing the EGF and mucin domains [34]. 
The O-glycosylation modifications within the mucin-like domain of CD93 contribute to 
stabilising its cell surface expression [157]. Intriguingly, the lack of O-linked glycosylation 
enhanced proteolytic cleavage of CD93 from the cell membrane and increased levels in 
culture medium. This provides a possible role for the mucin-like region within all the CTLD 
group 14 family members in preventing proteolytic cleavage, and also offers a potential 
mechanism of modulating surface cleavage events. The cell surface expression of CD93 is 
regulated by protein kinase C isoenzymes [158], and shedding could be enhanced by 
phorbol 12-myristate 13-acetate (PMA) a potent activator of protein kinase C [159].  
Upon knockdown of MMRN2, together with inhibition of new protein synthesis by 
cycloheximide treatment, cell surface CD93 levels were shown to be diminished whereas 
soluble CD93 levels increased [146]. This suggests that the interaction with MMRN2 may 
render CD93 less susceptible to proteolytic cleavage and hence this recognition event is 
important for regulating stable cell surface expression of CD93.  
 
Additional roles for CD93 
A study examining CD93 expression in neurons and microglia revealed that upon response 
to LPS mediated inflammation, the cytoplasmic tail of CD93 could be detected in the 
cytoplasm and nucleus [125]. This is the first instance that a possible gene expression 
modulating role has been inferred for the CD93 cytoplasmic region. As CD93 ECD cleavage 
is enhanced by LPS, and the cytoplasmic domain can be detected even after cleavage [148], 
it is possible that it translocates to the nucleus after ECD shedding, similar to that described 
for notch ECD [160]. The authors did not confirm whether nuclear localisation followed CD93 
ECD cleavage and further work is warranted in order to define the precise molecular 
mechanisms underlying this effect. Notably, similarities have been proposed between CD44 
and CD93 [148] as the CD44 ECD can be cleaved by ADAM10 and its intracellular domain 
by γ-secretase, similar to that described for notch receptors [161]. 
CLEC14A 
C-type lectin family 14 member A (CLEC14A) is a type I single pass transmembrane 
glycoprotein and considered to be endothelial specific. It was described as a novel 
endothelial specific gene identified by microarray analysis and data mining, and referred to 
as an unidentified expression sequence tag (EST) (accession number AW770514) [162]. 
CLEC14A was initially classified as a tumour endothelial marker based on 
immunohistochemical staining of multiple distinct tumour types, with strong staining on 
tumour associated vessels in contrast to a near absence of staining in healthy tissues [163]. 
Upregulation of CLEC14A at the mRNA level was also described in non-small cell lung 
cancer (NSCLC) tissues compared to healthy lung [164]. Interestingly, high expression of 
CLEC14A in this cancer type correlated with improved clinical outcomes. A further study 
indicated that the methylation status of CLEC14A strongly correlated with its expression 
levels in NSCLC, and CLEC14A protein levels were reduced in tumour tissues compared to 
healthy adjacent tissue [165]. Similarly to CD93, CLEC14A was described as a key gene in a 
proposed “tumour angiogenesis signature” determined by meta-analysis of over 1000 
tumour samples including breast, renal and head and neck cancers [131]. It was 
subsequently found to be upregulated at the protein level and increased with tumour 
progression in two different spontaneous mouse tumour models, namely cervical and 
pancreatic [152]. CLEC14A along with CD93 are downregulated in response to bevacizumab 
therapy, emphasising their pro-angiogenic roles (Bais et al. 2011). More recently, CLEC14A 
overexpression on the vasculature in ovarian cancer has been reported but did not correlate 
with survival in this tumour type [166]. The authors also demonstrated that CLEC14A 
expression was undetectable along with reductions in microvessel density in patients 
receiving neo-adjuvant chemotherapy prior to surgery. 
CLEC14A expression 
CLEC14A has been described to be upregulated by low shear stress [163]. Indeed 
application of 2 Pa of laminar shear flow to HUVEC in culture leads to a significant reduction 
(>90%) of CLEC14A expression. This may explain the expression of CLEC14A observed 
within the ill-formed vessels of tumours that experience poor blood flow and low shear stress 
[167]. Upstream regions of the CLEC14A gene in humans contain predicted Sp1 
transcription factor binding sites. Interestingly, Sp1 is phosphorylated in response to shear 
stress and can inhibit expression of MT1-MMP in endothelium [168]. Microarray analysis of 
atherosclerosis patient samples revealed upregulation of CLEC14A in vessels that display 
high levels of stenosis [169]. This is consistent with previous findings, as shear stress is 
lower in blood vessels containing atherosclerotic plaques when compared with healthy 
controls [170]. CLEC14A expression has also been linked with hypoxia in HUVEC, and could 
explain its greater expression in the tumour vasculature [171].  
CLEC14A (or C1qrl in zebrafish) is thought to be located downstream of the master 
endothelial and haematopoietic regulatory transcription factor etsrp in zebrafish (ETV2 in 
humans) [172]. The etsrp transcription factor has recently been implicated in tumour 
angiogenesis in xenograft models of melanoma and sarcoma in zebrafish embryos [173]. 
During zebrafish development clec14a is expressed at 24 hours post fertilisation  and 
morpholino knockdown of gene expression can have detrimental effects on vasculature 
formation [163]. Interestingly, following reintroduction of human CLEC14A mRNA into these 
knockdown zebrafish embryos, the vasculature reverted back to a normal phenotype 
showing the correct zebrafish homologue was targeted and highlighting the conserved 
nature of these genes. 
Mouse embryos display expression of CLEC14A in inter-segmental vessels and vessels in 
the developing brain, at embryonic day 10.5 [174]. Expression was also detected in the 
vessels of mouse retinas at postnatal day 12, which are constantly undergoing development 
after birth. CLEC14A has also been described as being upregulated when endothelial 
progenitor cells differentiate into outgrowth endothelial cells [175]. Clec14A has further been 
identified in higher levels in CD109+ circulating endothelial cells when compared to CD146+ 
circulating endothelial cells Finally, CLEC14A has been proposed as a marker for circulating 
endothelial cells localised in the blood of cancer patients [176]. 
CLEC14A expression has been demonstrated in two different human lung cancer cell lines 
in vitro and when CLEC14A was further overexpressed in these cell lines, this led to 
reductions in proliferation, migration and invasion as well as in vivo tumour formation as 
xenografts in nude mice [165]. 
CLEC14A shedding 
CLEC14A can be shed from the endothelial cell membrane by the thrombomodulin cleaving 
protease RHBDL2 [177]. RHBDL2 cleaves at a site close to the transmembrane domain, 
liberating the intact ECD of CLEC14A to regulate sprouting angiogenesis. The CLEC14A-
ECD can mediate anti-angiogenic effects in vitro and in vivo when utilised as an Fc tagged 
recombinant protein. Intriguingly, when used as a staining reagent the CLEC14A-ECD-Fc 
fusion bound to sprouting endothelial cells, predominantly tip cells. Therefore, one could 
propose a scenario in which shedding of CLEC14A may aid in regulation of sprouting 
angiogenesis. Such cleaved CLEC14A predominantly by stalk cells in an angiogenic sprout 
would then bind be able to bind to tip cells. From a diagnostic perspective soluble CLEC14A 
has been detected in the urine of patients with low grade bladder cancer, suggesting its 
potential utility as a tumour specific biomarker [178]. 
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CLEC14A interaction partners and biology 
The requirement for CLEC14A in various in vitro angiogenesis assays were reported by two 
independent groups utilising siRNA mediated knockdown of CLEC14A [163,174]. Based on 
these knockdown experiments the ability of HUVEC to form tubes and close wounded 
monolayers in scratch assays was compromised. In addition, involvement of CLEC14A in 
sprouting angiogenesis was demonstrated by siRNA knockdown of CLEC14A in HUVEC 
which led to marked reduction in sprout formation based on spheroid assays, CLEC14A 
deficient cells were also less likely to be found as tip cells in these sprouts [179]. Ectopic 
expression of CLEC14A in cells that do not normally express it results in formation of 
filopodia-like protrusions [163]. Altogether these findings implicate CLEC14A in filopodia 
formation, a vital step in sprouting angiogenesis. 
The involvement of CLEC14A in angiogenesis is reinforced by in vivo experiments 
performed in homozygous CLEC14A knockout mice [179]. These mice remained viable and 
displayed no gross developmental defects. Nevertheless, when challenged with 
subcutaneous Lewis lung carcinoma (LLC), tumour growth and tumour angiogenesis were 
reduced relative to wild type controls. Similarly, in subcutaneous sponge implants FGF-2-
induced angiogenesis were also impaired. However, another report has suggested that 
CLEC14A may not serve as a viable anti-vascular target, this study demonstrated that 
although implanted tumour growth of LLC and B16F10 melanoma was markedly impaired in 
CLEC14A knock-out mice in comparison to wild type littermates, tumour bearing CLEC14A 
knock-out mice died earlier [180]. These deleterious effects were attributed to reduced 
pericyte coverage and CLEC14A deficient vessels displaying increased permeability. 
Furthermore, this study revealed that CLEC14A deficiency led to increased lung metastasis 
burden when B16F10 cells were injected intravenously or into the foot pad. 
The CLEC14A CTLD has been implicated in cell-cell adhesion interactions, since CLEC14A 
overexpressing HEK293F cells have the ability to initiate preliminary cell-cell aggregates, 
which can be abolished following incubation with CTLD specific CLEC14A antibodies [181]. 
These antibodies were reactive against both human and mouse CLEC14A forms and could 
downregulate CLEC14A levels on the surface of HUVEC, posing a potential for 
internalisation of antibodies, and possible utilisation as ADCs carrying a cytotoxic payload. 
Finally, these antibodies could reduce HUVEC cell migration and tube formation based on in 
vitro assays. Further studies optimised the solubility and stability of the CLEC14A CTLD 
targeting antibodies and showed that they could block angiogenesis in mouse models 
utilising Matrigel plugs injected with recombinant VEGF or human tumour cells [182]. 
Collectively, these results suggest that the CTLD of CLEC14A has functional roles in 
angiogenesis.  
CLEC14A has been described as a component of HUVEC ECM which binds to the ECM 
glycoprotein MMRN2 [152]. Like CLEC14A, MMRN2 protein was upregulated with tumour 
progression of two different spontaneous mouse cancer models, highlighting importance of 
this interaction and potential as therapeutic tumour vascular targets [152]. The CLEC14A-
MMRN2 interaction could be blocked by a monoclonal antibody specific for CLEC14A, and 
when administered intraperitoneally retarded growth of subcutaneously implanted LLC in 
mice [179]. This interaction was dependent upon a predicted long-loop region encompassing 
residues 97-108 within the CLEC14A CTLD [90]. The CLEC14A-MMRN2 interaction could 
also be targeted using a minimal peptide fragment derived from MMRN2. This peptide 
reduced endothelial tube formation and also decreased tumour growth when expressed by 
LLC cells in vivo [90]. 
The CLEC14A CTLD also has the capacity to bind other ligands including the heat shock 
protein 70 kDa 1A (HSP70-1A) which increased HUVEC adhesion, aggregation and ERK 
phosphorylation [183]. This finding may rationalise the cell aggregation effects observed in 
HEK293F cells overexpressing CLEC14A, with HSP70-1A forming oligomeric complexes 
and creating a bridge between CLEC14A expressed on different cells. This binding 
phenomenon was dependent on amino acids 43-69 of the CLEC14A CTLD [183], which 
based on its predicted structure encompasses an alpha helical region that is distal to the 
MMRN2 binding site. However, at present it is unclear whether HSP70-1A and MMRN2 are 
mutually exclusive binding events or if they compete with each other [90]. The same group 
previously discovered that HSP70-1A could serve as a potent pro-angiogenic factor [184]. 
The active HSP70-1A binding region of CLEC14A fused to an Fc tag was used to create a 
novel peptibody which could inhibit HSP70-1A stimulated tubule formation of HUVEC in vitro 
[183]. In the same study stimulation of HUVEC with HSP70-1A increased ERK 
phosphorylation, and this effect was reduced when incubating with CLEC14A CTLD-Fc 
fusion proteins. This suggests that CLEC14A may have signalling roles, although the 
authors did not probe whether HSP70-1A mediated ERK phosphorylation was blocked with 
knockdown of CLEC14A. 
The intracellular domain of CLEC14A reportedly interacts with vascular endothelial growth 
factor receptor-3 (VEGFR-3), a process which modulates activity of VEGFR-2 [180]. There 
are currently no other known interactors for the CLEC14A cytoplasmic domain, although 
global phosphoproteomic analysis of HUVEC has revealed the presence of five serine 
residues that can be phosphorylated, namely S437, S445, S483 S487 and S488 [185,186]. 
The phosphorylated S483 was also found in other proteomic analyses and was described as 
being close to a predicted PDZ binding domain in the CLEC14A cytoplasmic domain [152]. 
Since these residues are not conserved in mouse CLEC14A the relevance of these post-
translational modifications will need to be determined experimentally. A summary of the 
protein interactions of CLEC14A are shown in Figure 6. 
 
CTLD group 14 family summary 
The CTLD group 14 family members all mediate effects upon the vasculature and some 
share remarkable similarities with respect to binding partners localised within the 
extracellular matrix. Further similarities are also observed with respect to expression 
patterns and regulation by predicted transcription factors. A summary of similarities and 
differences are displayed in table 1. 
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Expression localisation of CTLD group 14 family members in vivo 
To gain an in-depth understanding of gene expression of all four CTLD group 14 family 
members in vivo we used the recently described Tabula Muris database, which consists of 
single cell transcriptomic analyses of over 100,000 cells derived from 20 different healthy 
adult mouse organs and tissues from C57BL/6 strain mice [187]. This allowed graphical 
representation of gene expression by use of t-SNE plots and revealed that thrombomodulin 
is mainly expressed in endothelium, epithelium and mesenchymal cell types, as well as 
some myeloid, pro B-cell and bladder cells (Figure 7). CD248 is restricted mainly to 
mesenchymal cells, fibroblasts, pericytes and bladder cells, and importantly there was a lack 
of expression of CD248 in endothelial cells from multiple organs. CD93 showed mainly 
endothelial, myeloid, pro B-cell and haematopoietic progenitor cell expression. Finally, 
CLEC14A exhibited the most endothelial specific expression of the four family members but 
also localised in bladder cells and leukocytes from the thymus. The cell types demonstrating 
the highest expression for each family member are displayed in Table 2. The endothelial 
expression of CTLD group 14 family members was then investigated further, t-SNE plots of 
all endothelial cells from different organs as well as pericytes from brain were created, 
showing that THBD is expressed in mostly all endothelial cell types, CD248 is not expressed 
in endothelial cells (but is expressed in pericytes) and CD93 and CLEC14A are expressed to 
a varied degree in most endothelial cells (Figure 8A). As CD93 and CLEC14A share the 
ligand MMRN2, are both expressed by endothelium, share similar endothelial phenotypes 
and have been suggested previously to compensate for lack of the other, we investigated 
whether endothelial cells in certain organs displayed differential expression of each gene. 
This revealed that CD93 is expressed higher than CLEC14A in a majority of organs except 
kidney (no significant difference) and liver, lung and pancreas endothelium, where CLEC14A 
is expressed significantly higher (Figure 8B). This suggests that there may be endothelial 
cells from certain organs where CD93 or CLEC14A plays a more dominant role. 
Interestingly, there appeared to be a subset of endothelial cells within the lung that do not 
express CD93 but do express CLEC14A, t-SNE plots solely of lung endothelium showed that 
there was a clustering of these cells suggesting an unknown endothelial subtype that does 
not express CD93 in mouse lung (Figure 8C). The tabula muris database provides novel 
interesting insights into expression patterns, at least at the gene expression level, in an adult 
healthy mouse, although this is not an exhaustive list of all mouse cell types that express 
these genes as only 20 major organs and tissues were analysed. Similar studies analysing 
single cell gene expression of mice in different disease states such as cancer or 




Similarities between CTLD group 14 family members 
All CTLD group 14 family members comprise 6 canonical cysteines in the CTLD that are 
predicted to form disulphide bonds and support the CTLD scaffold. They also encompass 2 
non-canonical cysteines located within the predicted long loop regions which due to their 
close proximity may also form disulphide links. Interestingly, such non-canonical cysteines 
within the long loop region are found only in three other CTLD families; group 8 containing 
layilin and chondrolectin, group 11 and group 12 
(http://www.imperial.ac.uk/research/animallectins/). Disulphide bond formation within this 
long loop appears to be essential for the interaction of CLEC14A and CD93 with MMRN2. 
Upon point mutation of these long loop cysteines, the CLEC14A CTLD folds correctly as it is 
recognised by conformation specific monoclonal antibodies, but completely diminishes  its 
binding capability with MMRN2 [90]. It is possible that the corresponding cysteines in CD248 
and thrombomodulin are similarly important for CTLD mediated recognition events and 
constructs containing point mutations of these residues could represent invaluable tools in 
determining functional relevance of the CTLD within this family.     
Thrombomodulin and CD93 are both anchored to the actin cytoskeleton by associating with 
ERM adapter proteins; thrombomodulin to ezrin and CD93 to moesin. The thrombomodulin-
ezrin interaction was initially described in epithelial cells and this is not surprising given that 
ezrin in this cell type is the highest expressed ERM protein. In contrast in endothelial cells 
moesin is the most abundantly expressed ERM protein [188]. Due to the high sequence 
homology between ezrin and moesin (~75% sequence identity) [189] it is tempting to 
speculate that thrombomodulin also interacts with moesin in the endothelium. However, the 
ability of thrombomodulin to bind to ezrin or moesin within endothelial cells is yet to be 
assessed. Likewise, CD93 may to bind to multiple ERM adapter proteins as is the case for 
CD44 binding to ezrin, radixin and moesin [190]. Both thrombomodulin and CD93 
interactions with ERM adapter proteins are dependent upon positively charged residues 
within the cytoplasmic tail, which are absent in the corresponding regions of CD248 and 
CLEC14A. This motif comprises of RKK in thrombomodulin and RKR in CD93. Strikingly, the 
RKE motif in CLEC14A could potentially abolish binding to ERM proteins due to repulsion 
effects attributable to the negatively charged glutamic acid side chain. Nevertheless, there is 
a distinct possibility that the intracellular domain of CLEC14A makes direct or indirect 
contacts with the cytoskeleton, due to its proposed roles in filopodia formation and cell 
migration.  Also, the corresponding region in the CD248 intracellular domain  consists of the 
NKR motif, and it is unclear whether the non-charged asparagine residue can compensate 
for binding to ERM adapter proteins. Finally, a related point to consider is that in both CD248 
and CLEC14A the three amino acid motif is preceded by a proline residue which may cause 
rigidity and/or conformational alterations that could affect interactions with ERM adapter 
proteins. 
Evidence for CLEC14A along with thrombomodulin acting as potential cell adhesion 
molecules is observed following overexpression of each protein and leads to induced cell 
aggregation. Such effects are dependent upon the CTLD of each protein [68,174,181]. 
HUVEC plated on immobilised fragments of MMRN2 are sufficient to allow adherence of 
HUVEC in cell binding assays, however at present it is unclear whether CLEC14A, CD93 or 
both mediate this adhesive function [90]. Similarly when CD248 is overexpressed in CHO 
cells this enables them to bind to fibronectin and Matrigel in cell adhesion assays [88]. 
CLEC14A and CD93 both bind MMRN2 as does CD248, this to our knowledge is the first 
example of an endothelial protein binding to an extracellular matrix protein which in turn 
interacts with a pericyte expressed protein of the same protein family. This raises an 
interesting question of how MMRN2 has evolved to bind two distinct CTLD group 14 family 
members in non-overlapping regions of the same molecule. This binding event may have 
roles in already proposed CD248 dependent vascular regression caused by pericytes [75]. In 
regards to CLEC14A expression and MMRN2 interaction, this may flag areas of the newly 
formed vasculature that is experiencing low blood flow and low shear stress. Upon binding to 
MMRN2 through CD248, pericytes could then selectively cause vascular regression through 
unknown mechanisms. Interestingly, pericyte coverage of endothelium is reduced in the 
brain, retina and melanoma tumour vasculature of CLEC14A knockout mice [180]. However, 
no defects were reported in pericyte coverage of vessels in models of gliomas between 
CD93 knockout and wild type mice [133]. This suggests that CLEC14A may have more 
predominant roles in pericyte attachment, or there could be differences in the requirement of 
CLEC14A or CD93 in pericyte attachment in different tissues. 
Although MMRN2 has been shown to be a substrate for MMP9, it is unclear whether the 
subsequent cleaved fragments can still bind to members of the CTLD group 14 family and 
clearly warrants further investigation [191]. Intriguingly, as mentioned previously, CD248 
overexpression results in upregulation of MMP9 posing a scenario in which MMRN2 could 
be processed by MMP9 and potentially regulate CD248-MMRN2 binding. Alternatively, 
CD248 mediated upregulation of MMP9 may allow cleavage of MMRN2 and detachment of 
the endothelial-pericyte interaction. 
It is uncertain whether CLEC14A and CD93 compete for binding with MMRN2 or whether 
they have independent or similar roles. Also, the signaling outcomes following MMRN2 
binding to CLEC14A, CD93 or CD248 are not fully established. CLEC14A and CD93 have 
been postulated to have redundant roles in zebrafish angiogenesis but not vasculogenesis 
[192]. Simultaneous knock-out of both CLEC14A and CD93  led to more severe defects in 
intersegmental vessel formation compared with single gene knock-outs. VE-cadherin 
expression was absent in vessels that lacked CLEC14A and CD93, suggesting 
abnormalities in endothelial cell-cell adhesion, when VE-cadherin was replaced this rescued 
the detrimental phenotype. Knockdown of CD93 has also been shown to reduce VE-
cadherin levels in HUVEC [133], although phenotypic outcomes following double knockdown 
of both CLEC14A and CD93 have not yet been reported in mammalian cell types. Currently 
there is no data on whether CLEC14A and CD93 display redundancy in mammals, and a 
double KO mouse would begin to address this important question. 
The EGF repeats and mucin-like regions of both CD93 and thrombomodulin have been 
reported to have pro-angiogenic effects. In the case of thrombomodulin, this mitogenic ability 
was abolished if the CTLD was present on the soluble protein (i.e. including the CTLD, sushi 
and EGF repeats), although it is unclear whether this also applies for CD93. Nevertheless, 
one could speculate a scenario where differential proteolytic cleavage of such proteins 
results in diverse outcomes upon the endothelium and other cell types, allowing fine tuning 
of cellular events. As discussed previously, there is evidence that the CTLD of 
thrombomodulin can be shed from the full length molecule or from the cleaved extracellular 
domain. Additionally, there is likely a second cleavage event in the CLEC14A ECD 
generating a fragment smaller than the full-length ECD which encompasses the CTLD [177]. 
Multiple proteolytic cleavage events may be true for other CTLD group 14 family members.  
It is currently unknown whether CLEC14A and CD93 share other extracellular binding 
partners as is the case for MMRN2. The region of CLEC14A that engages HSP70-1A 
exhibits 29.6% sequence identity to CD93. However, the long loop stretch shown to be 
important for binding to MMRN2 within both CLEC14A and CD93 shares 32.6% sequence 
identity. Clearly further binding experiments to extensively characterise interactions between 
other CTLD group 14 family members and this newly described ligand will need to be 
conducted. 
Potential roles in immunosuppression 
Angiogenesis and immunosuppression are two tightly regulated processes that often occur 
in unison. They have been described as parallel processes especially in the context of 
tumour angiogenesis and tumour immunosuppression [193]. Many pro-angiogenic proteins 
also mediate immunosuppressive effects upon the vasculature as well as immune cells 
directly [194]. Here we describe some examples of CTLD group 14 family members that illicit 
immunosuppressive roles. For example, expression of CD248 on naïve T-cells correlated 
with decreased cell proliferation. In this setting CD248 binding to its ligands that are 
upregulated in tumour angiogenesis, (i.e. MMRN2 or fibronectin etc.) may inhibit T-cell 
proliferation. Similarly, thrombomodulin expression on the vasculature or perhaps in soluble 
form can mediate immunosuppressive functions upon binding GPR15 on T-cells as well as a 
whole host of other anti-inflammatory roles as described above. Although high expression of 
thrombomodulin has been reported by multiple groups in diverse cancer indications, whether 
thrombomodulin can actually illicit an immunosuppressive function in the context of cancer 
remains to be elucidated and the finding that low thrombomodulin leads to improved 
prognosis seems to contradict this theory. CD93 has also been described to trigger anti-
inflammatory events, such as limiting leukocyte migration in peritonitis [140].  Other 
members of the CTLD group 14 family may invoke broader effects upon distinct components 
of the immune system, and potentially contribute to immunosuppression especially in the 
context of tumours evading the immune system. 
Potential use as therapeutic targets 
The phenomenon of tumour cells binding to and co-opting the endothelium of highly 
vascularised organs poses an interesting question for potential roles of the CD248-MMRN2-
CD93/CLEC14A interactions. For example since sarcoma and neuroblastoma tumour types 
express CD248, it is conceivable that these cells upon binding to endothelium derived 
MMRN2 may allow adhesion and contribute to key processes such as metastatic seeding or 
newly emerging mechanisms of tumour blood vessel acquisition, namely vessel co-option or 
pericyte mimicry [195,196]. Indeed, CD248 has been highly pursued as a cancer target, with 
considerable focus on tumour types that express high levels of this protein such as sarcoma. 
So far clinical trials have proved to be been somewhat disappointing, and these CD248 
targeting agents may only be effective in certain tumour types or need to be combined with 
other therapeutics for optimal clinical benefit. 
CLEC14A as a therapeutic target of the tumour vasculature has been investigated by many 
different preclinical strategies using antibodies as well as fragments of its known ligands and 
even chimeric antigen receptor (CAR) T-cells [197,198]. Since it is well established that 
CLEC14A is expressed on vessels that experience low shear stress and aberrant blood flow, 
it is conceivable that only non-functional tumour vessels will be targeted by such agents. 
This could prove beneficial as vascular normalisation effects would likely take place, 
lowering hypoxia, which could lead to better accumulation and delivery of other drugs used 
in combination such as chemotherapy. Additionally, such CLEC14A targeting could be 
combined with immunotherapies which rely on infiltration of effector immune cells into the 
tumour mass, where functional and more “normal” vasculature would likely be advantageous 
[98]. 
In studies investigating the use of CLEC14A CTLD specific antibodies Kim et al. tested a 
human colorectal cancer cell line HCT116 as well as a bevacizumab resistant version of this 
line. Both cell lines showed significant reductions of in vivo angiogenesis following treatment 
with CLEC14A antibodies when these cells were embedded in Matrigel and injected 
subcutaneously [182]. This suggests a possible use for targeting of CLEC14A in patients 
that have acquired resistance to VEGF blockade. More importantly these findings suggest 
that although targeting of CLEC14A can reduce VEGF dependent angiogenesis in various 
models, it may also ablate angiogenesis induced by VEGF independent pathways. However, 
the authors did not assess the efficacy of these antibodies in targeting this resistant cell line 
in tumour xenograft studies, therefore the tangible benefit of CLEC14A targeting in tumour 
types resistant to VEGF blockade is yet to be fully established. 
Dual targeting of CLEC14A and CD93 was achieved by use of a MMRN2 fragment that 
contained the CTLD binding region (amino acid residues 495-674 in human and 495-678 in 
mouse) fused to an Fc tag [90]. This resulted in a decrease in syngeneic tumour growth in 
vivo and disruptions in angiogenesis in vitro. Blocking CLEC14A and CD93 in this manner 
will likely inhibit endothelial cells binding to endogenous MMRN2 and may even interrupt the 
fibrogenesis of fibronectin, as has been described with genetic ablation of CD93 [146]. 
Furthermore such targeting strategies may destabilise the binding of CD248 expressing 
pericytes to the tumour vasculature, although whether this affects pericyte coverage remains 
to be investigated. There is scepticism in the field in terms of whether such approaches 
provide meaningful clinical benefit [146,199]. The use of dual targeting approaches negates 
the ability of one protein compensating the loss of the other. However, it is important to note 
that this dual targeting MMRN2 fragment Fc fusion protein was expressed directly in the 
tumour microenvironment by genetically engineered tumour cells. With less restricted 
expression of the targeting fragment, we cannot rule out the possibility that this agent could 
display off target effects by binding to other CD93 expressing cell types such as monocytes 
or B-cells. 
The likelihood of CTLD group 14 family members serving as viable targets in cancer therapy 
will ultimately depend on the expression profile of these proteins, which if not tumour or 
tumour vasculature specific could result in toxicity related issues in patients. In this regard a 
seminal paper investigating targeting the tumour endothelial marker and immunomodulatory 
molecule CD276 (also referred to as B7-H3) described that the most important determining 
factor for avoiding toxicity is in fact level of expression [200,201]. Indeed, even though 
CD276 displays a widespread expression pattern in mouse and human tissues, the fact that 
it is so highly expressed by tumour cells and the associated tumour vasculature, resulted in 
antibody drug conjugates against CD276 only having substantial effects upon the tumour 
microenvironment. In light of this data, experiments that determine levels of target protein 
expression will likely become paramount.  Relatedly, low affinity high avidity therapeutic 
agents could be used against targets that are highly expressed on tumour associated tissue 
but still expressed lowly on normal tissue, in this way agents would preferentially bind to 
highly expressing cell types. This approach was demonstrated with low affinity, high avidity 
HER-2/CD3 binding bispecific agents that redirect T-cells towards breast cancer cells [202]. 
These high avidity bispecific antibodies induced negligible effect on in vivo tumour models 
expressing low levels of HER-2 but successfully eradicated high expressing tumour lines, 
suggesting that normal tissues expressing HER-2 at low levels may be avoided and toxicity 
minimised. Furthermore, experiments investigating whether these proteins can be physically 
targeted in vivo are of vital importance. As part of this process it is conceivable that in vivo 
tracking of antibody or other biological agents could be performed by radiolabelled 
biodistribution experiments or fluorescent labelling as previously described for antibodies 
against fibronectin extra domain B [203]. 
As mentioned previously, the cleavage of the CTLD group 14 family members may 
negatively impact antibody targeting therapies, as the soluble forms may sequester the 
antibodies in the blood rendering them incapable of binding to the cell surface receptors. 
However, this issue will likely be addressed in preclinical models and presumably be 
overcome in phase I dose escalation studies of CTLD group 14 family targeted agents. 
 
Concluding remarks 
The CTLD group 14 is an emerging family of molecules with diverse roles in the vasculature, 
inflammation as well as tumour progression. The increasing interest in these molecules 
including elucidation of their normal biology as well as their potential as therapeutic targets in 
cancer will likely continue to flourish.  
 
  
 CTLD group family Number of total cysteines 
in CTLD 
Cysteines in long loop 
region, between core WIGL 
and other hydrophobics 
Group 1 Proteoglycans 6 None 
Group 2 Type II receptors 8 None 
Group 3 Collectins 4 None 
Group 4 Sellectins 4 None 
Group 5 NK cell receptors 6 or 7 or 8 or 9 None 
Group 6 Macrophage 
Mannose receptor family 
4 or 6 None 
Group 7 Free CTLD  6 None 
Group 8 Simple Type I  8 Yes 
Group 9 Tetranectin 6 None 
Group 10 Polycystin 6 or 7 No (just one on long loop) 
Group 11 Attractin 5 Yes 
Group 12 CTLD acidic neck 10-11 Yes 




Group 15 CLEC18A 6 No 
Group 16 Proteoglycans 6 No 
 
  
Figure 1. CTLD group 14 family proteins. Schematic diagrams of the CTLD group 14 
family proteins. Each protein is drawn to relative scale based on primary amino acid 
sequence length. The CTLD is shown in red, the sushi in blue and the EGF repeats in green. 
 
Figure 2. Cladogram of CTLD group 14 family members based on sequence 
alignment. Cladogram was constructed from alignments of the whole primary sequence of 
each family member using Clustal Omega (Sievers et al. 2011). (B) Table of percentage 
amino acid identity between family members. The following protein sequences were used 
thrombomodulin (P07204), CD93 (Q9NPY3), CLEC14A (Q86T13) and CD248 (Q9HCU0). 
CLEC14A is most closely related to CD248 and thrombomodulin most closely related to 
CD93. 
 
Figure 3. Schematic of thrombomodulin protein structure with ligand binding 
partners. Thrombomodulin CTLD has been shown to interact with fibronectin, HMGB1, 
Kringle 1-5 and Lewis Y antigen. The CTLD may be proteolytically cleaved by an as yet 
unidentified MMP. Thrombin binds to the 5th and 6th EGF domains, this binding is in 
competition with Ang1 and/or Ang2. RHBDL2 can cleave the whole extracellular domain of 
thrombomodulin as can neutrophil elastase, cathepsin G and proteinase 3. The cytoplasmic 
tail binds to ezrin which in turn links thrombomodulin to the actin cytoskeleton. 
 
Figure 4. Schematic of CD248 structure with ligand binding partners. CD248 CTLD 
binds to fibronectin, Mac-2 BP, Collagens I and IV and MMRN2. There are currently no 
known direct intracellular interaction partners for CD248. 
 
Figure 5. Schematic of CD93 structure with ligand binding partners. CD93 CTLD binds 
to MMRN2. The whole extracellular domain has been shown to be cleaved by an as yet 
unidentified metalloproteinase. The intracellular cytoplasmic domain binds to moesin which 
in turn links CD93 to the actin cytoskeleton. The cytoplasmic domain also binds to Cbl and 
GIPC1 and src.  
 
Figure 6. Schematic of CLEC14A protein with ligand binding partners. CLEC14A CTLD 
binds to MMRN2 and to HSP70-1A. The whole extracellular domain can be cleaved by 
RHBDL2. There are currently no known direct intracellular partners for CLEC14A. 
 
Figure 7. Expression of CTLD group 14 family members in mouse tissues. The Tabula 
Muris database was used to determine which mouse cell types expressed each CTLD group 
14 family gene from data acquired through fluorescence activated cell sorting and single cell 
gene expression analysis. The t-SNE plot at the top displays annotations of each cell type 
and shows a legend of colours corresponding to which organ or tissue type that cell was 
from. The lower t-SNE plots display in which cell types each family member was expressed 
(purple). 
 
Figure 8. Endothelial expression of CTLD group 14 family members in mouse tissues. 
(A) The tabula muris database was used to create t-SNE plots of all endothelial cells from 
different organs as well as brain pericytes. The t-SNE plot at the top left displays a legend of 
colours corresponding to which organ or tissue type that cell was from. Expression of each 
CTLD group 14 family member within these cell types are displayed as t-SNE plots. (B) 
Single cell sequencing data analysed as fragments per kilobase million (FPKM) was used to 
compare CD93 and CLEC14A expression in different endothelial cells from different organs. 
Wilcoxon statistical test was used to compare ****p≤0.0001. (C) t-SNE plots of lung 
endothelium alone were created which revealed the presence of a cluster of cells expressing 
low levels of CD93 when compared with all other lung endothelial cells but similar levels of 
CLEC14A (grey ellipse).   
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